Accelerated Approval, Arava, Factive Are Topics For Early 2003 Committees
FDA's accelerated approval policies for cancer agents, a review of GeneSoft's Factive, and a safety update for Aventis' rheumatoid arthritis drug Arava are among the topics for advisory committees in early 2003
You may also be interested in...
FDA will take regulatory action on AstraZeneca's Iressa (gefitinib) by May 5
FDA is planning an advisory committee meeting to discuss the accelerated approval process for oncologic agents
FDA will reduce its total advisory committee count to 30 with the termination of the Pharmacy Compounding and Medical Imaging Drugs Advisory Committees